ReviewTherapeutic advances in hematology2018

Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Polina Shindiapina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.